Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE: Safety of aPCC Following Emicizumab Prophylaxis in Hemophilia A
NCT04563520Phase 3Recruiting
- Sponsor
- Emory University
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anti-inhibitor coagulant complex in hemophilia A, sponsored by Emory University. Primary endpoint: Thrombin generation capacity after aPCC (FEIBA) infusion at 30 minutes. Started Sep 2026; status: recruiting.
02
Drugs
anti-inhibitor coagulant complex
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04563520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563520.